GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » X4 Pharmaceuticals Inc (STU:48Q) » Definitions » EV-to-FCF

X4 Pharmaceuticals (STU:48Q) EV-to-FCF : -0.36 (As of Dec. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is X4 Pharmaceuticals EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, X4 Pharmaceuticals's Enterprise Value is €43.44 Mil. X4 Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was €-121.94 Mil. Therefore, X4 Pharmaceuticals's EV-to-FCF for today is -0.36.

The historical rank and industry rank for X4 Pharmaceuticals's EV-to-FCF or its related term are showing as below:

STU:48Q' s EV-to-FCF Range Over the Past 10 Years
Min: -2.65   Med: -0.04   Max: 0.47
Current: -0.34

During the past 9 years, the highest EV-to-FCF of X4 Pharmaceuticals was 0.47. The lowest was -2.65. And the median was -0.04.

STU:48Q's EV-to-FCF is ranked worse than
100% of 387 companies
in the Biotechnology industry
Industry Median: 8.7 vs STU:48Q: -0.34

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-13), X4 Pharmaceuticals's stock price is €0.594. X4 Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.066. Therefore, X4 Pharmaceuticals's PE Ratio (TTM) for today is At Loss.


X4 Pharmaceuticals EV-to-FCF Historical Data

The historical data trend for X4 Pharmaceuticals's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X4 Pharmaceuticals EV-to-FCF Chart

X4 Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -1.44 -1.07 -0.31 -0.49 -0.87

X4 Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.09 -0.87 -2.03 -0.06 -0.42

Competitive Comparison of X4 Pharmaceuticals's EV-to-FCF

For the Biotechnology subindustry, X4 Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


X4 Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, X4 Pharmaceuticals's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where X4 Pharmaceuticals's EV-to-FCF falls into.



X4 Pharmaceuticals EV-to-FCF Calculation

X4 Pharmaceuticals's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=43.441/-121.939
=-0.36

X4 Pharmaceuticals's current Enterprise Value is €43.44 Mil.
X4 Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-121.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


X4 Pharmaceuticals  (STU:48Q) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

X4 Pharmaceuticals's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.594/-0.066
=At Loss

X4 Pharmaceuticals's share price for today is €0.594.
X4 Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.066.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


X4 Pharmaceuticals EV-to-FCF Related Terms

Thank you for viewing the detailed overview of X4 Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


X4 Pharmaceuticals Business Description

Traded in Other Exchanges
Address
61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

X4 Pharmaceuticals Headlines

No Headlines